Back to News
Market Impact: 0.42
Datos de fase III de olatorepatida --agonista dual sesgado de GLP-1/GIP de Hansoh-- presentados en la EASD
Source: PR Newswire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Hansoh presented Phase III data at the EASD meeting in Milan showing its dual GLP-1/GIP agonist olatorepatida achieved 19.3% weight loss at week 48. The result is a strong clinical efficacy signal in the obesity-treatment market and could improve the drug's competitive positioning, though the article excerpt provides no safety data, comparator results, or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Anthropic warns government attitudes may hurt customer ties, IPO prospectus shows: Reuters
- Your health insurance premiums may take a big jump in 2027 — here's why
- Paramount and Warner Bros. Discovery to Merge Into Skydance (SKYD). Will Skydance Achieve David Ellison’s "Quality Storytelling" Vision?
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template